AAV vector based gene therapy (RegenX Biosciences)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAAV vector based gene therapy (RegenX Biosciences)
Drug Alias Nameheparan N-sulfatase gene therapy (RegenX Biosciences)adeno-associated virus vector based gene therapy(RegenX Biosciences)
ClassificationBiologics
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegenxbio Inc
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis III

Other Information

ATC CodeN/A
Related LinksN/A